Navigation Links
Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
Date:2/12/2013

ANAHEIM, Calif., Feb. 12, 2013 /PRNewswire/ -- Bluestar Silicones will show its Silbione® brand soft silicone technologies at the Medical Design & Manufacturing (MD&M) West Conference  (Booth #1761), February 12-14.  These technologies include low durometer liquid silicone rubber (LSR), room temperature vulcanized (RTV) silicones, gels and skin adhesives, and its new patent pending silicone foam.

Technical Leader Dr. Umar Latif , Ph.D., will present "Soft Silicones Offer Unique Advantages for Healthcare Applications," in the Innovation Brief Theater on Thursday, February 14 at 11:30 a.m.

According to Dr. Latif, unique physical performance attributes such as high tear strength and elongation, can now be achieved in very low durometer soft silicones, enabling a much broader range of applications in the healthcare arena.

Bluestar Silicones' new 1 Shore A hardness product, Silbione LSR 4301, uniquely combines strong physical properties and easy processing in a low-durometer material. The product rounds out Bluestar Silicones' -05 and -10 ShA soft LSR range, delivering high tear strength and high elongation for soft cushioning and vibration dampening applications.

The company's patent pending silicone foam technology offers low density open cell silicone foam for flexible, breathable yet durable applications.  This innovation was honored as Frost & Sullivan's Product Differentiation Award in 2012.

In addition to its soft silicone technologies, Bluestar Silicones offers a full range of silicone technologies for the healthcare industry including LSR, high consistency rubbers (HCR), room-temperature vulcanized silicones (RTVs), skin adhesive tacky gels, cushioning gels and permanent adhesives. 

Most of these healthcare grade technologies are manufactured in Bluestar Silicones new facility located in York, S.C., which opened in June 2012.

About Dr. Latif
Dr. Umar Latif , Ph.D. is the Technical Service Manager for Bluestar Silicones' Elastomeric Markets. His areas of expertise include LSR, HCR, RTV, gel, skin adhesive and foam silicone technologies.  Dr. Latif holds a Ph.D. and an M.S. degree in polymer chemistry/silicone polymers from City University of New York.  He completed his B.S. in chemical technology and biotechnology from Saint-Petersburg State Institute of Technology, Saint-Petersburg, Russia.

About Bluestar Silicones
With worldwide operations headquartered in Lyon, France, Bluestar Silicones is a $650 million worldwide silicones raw material manufacturer. The company is one of the world's leading fully integrated global silicones manufacturers with more than 60 years of silicone expertise. Bluestar Silicones has manufacturing operations throughout the world and combines upstream silicon metal operations and capacity with downstream silicone market and application development expertise. The company offers a comprehensive range of silicone technologies in support of diverse specialty markets including paper release, textile coatings, healthcare, moldmaking, automotive, aerospace, and personal care. For more information, call (866) 474-6342 or visit www.bluestarsilicones.com.

Press contact: Karen O'Keefe, E-mail:  Karen.okeefe@bluestarsilicones.com
Phone:  732-227-2089 – Fax:  732-249-7000

                     


'/>"/>
SOURCE Bluestar Silicones
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
3. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
4. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
5. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
6. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
7. Fusion presents low proliferation risk, experts conclude
8. ODT Forum Presents Regenerative Technologies
9. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
10. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
11. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... FRANCISCO , Feb. 24, 2017 Symic ... is developing a new category of therapeutics, announced today ... of SB-030 in peripheral artery disease. The trial will ... administered single-use therapeutic, in the reduction of restenosis following ... this critical development milestone for SB-030," said Nathan ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive small ... FireflySci had the goal of bringing their powerful cuvette and spectrophotometer calibration ... path that FireflySci is going on as they add yet another mark on the ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is formalizing ... an array of biochemical analyses critical for Lead Discovery. The company’s Lead ... SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor residence ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):